Merck said the deal will enable it to expand its portfolio with CD388, a long-acting antiviral aimed at preventing flu in people at high risk of complications.
Merck said the deal will enable it to expand its portfolio with CD388, a long-acting antiviral aimed at preventing flu in people at high risk of complications.